Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625738 | 0.83 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL27513000 | 0.83 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2435573 | 0.82 | MEN1 (0.68) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL14422990 | 0.81 | MEN1 (0.82) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL28119259 | 0.81 | NPC1 (0.60) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL12613966 | 0.78 | VNN1 (0.51) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL387258 | 0.77 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL1227061 | 0.77 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL28643702 | 0.77 | MEN1 (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL13364852 | 0.77 | NR1H4 (0.47) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| CN-102209710-A | Pyrrolidines | PFIZER LTD | 2011-10-05 | — | — | CN | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2155666-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | Pfizer Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139287-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139287-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | NPC1 4756/4885RAB9A 2743/4885MEN1 1931/4885 |
| US-20080280877-A1 | Azetidines | PTGER2, PTGER1, PTGDR2 | NPC1 3819/4885RAB9A 883/4885MEN1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.